CNTA - Centessa Pharmaceuticals | Satya Bio Analysis

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a pipeline of orexin receptor 2 (OX2R) agonists. The company's asset-centric model concentrates resources on its orexin franchise, with lead program ORX750 in Phase 2a for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), and two follow-on molecules (ORX142, ORX489) extending the platform into neurodegeneration and neuropsychiatry.

Investment Thesis

Bull Case

ORX750 Phase 2a showed best-in-class wake promotion across all three populations (NT1, NT2, IH) - first OX2R agonist to achieve this
Registrational-ready with clear path forward and well-characterized dose-response relationship
NT2 and IH have massive unmet need - ORX750 could become new standard of care in NT2
Three-molecule franchise provides multiple shots on goal across neuroscience
Clean safety profile - all AEs mild-moderate and transient

Bear Case

Orexin agonist class is competitive - Takeda, Harmony Biosciences, and others have programs
Phase 2a data on 55 patients is still relatively small - registrational trial is the real test
Single-target platform risk: if OX2R agonism doesn't translate broadly, pipeline value narrows
UK-headquartered company may face challenges in US commercial build-out
No revenue until potential approval - pure clinical-stage risk

Pipeline

Asset	Target	Stage	Lead Indication	Next Catalyst
ORX142	OX2R	Phase 1	Neurological and neurodegenerative disorders	Patient study initiation (Q1 2026)
ORX489	OX2R	IND-enabling	Neuropsychiatric disorders	First-in-human clinical studies (2026)
ORX750	OX2R	Phase 2a	Narcolepsy Type 1 (NT1)	Registrational program initiation (Q1 2026)

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy